Urocortin-1 Is Chondroprotective in Response to Acute Cartilage Injury via Modulation of Piezo1

Int J Mol Sci. 2022 May 4;23(9):5119. doi: 10.3390/ijms23095119.

Abstract

Post-traumatic OA (PTOA) is often triggered by injurious, high-impact loading events which result in rapid, excessive chondrocyte cell death and a phenotypic shift in residual cells toward a more catabolic state. As such, the identification of a disease-modifying OA drug (DMOAD) that can protect chondrocytes from death following impact injury, and thereby prevent cartilage degradation and progression to PTOA, would offer a novel intervention. We have previously shown that urocortin-1 (Ucn) is an essential endogenous pro-survival factor that protects chondrocytes from OA-associated pro-apoptotic stimuli. Here, using a drop tower PTOA-induction model, we demonstrate the extent of Ucn's chondroprotective role in cartilage explants exposed to excessive impact load. Using pathway-specific agonists and antagonists, we show that Ucn acts to block load-induced intracellular calcium accumulation through blockade of the non-selective cation channel Piezo1 rather than TRPV4. This protective effect is mediated primarily through the Ucn receptor CRF-R1 rather than CRF-R2. Crucially, we demonstrate that the chondroprotective effect of Ucn is maintained whether it is applied pre-impact or post-impact, highlighting the potential of Ucn as a novel DMOAD for the prevention of injurious impact overload-induced PTOA.

Keywords: cell survival; chondrocyte; chondroprotection; explant; injury; loading; osteoarthritis; post-traumatic osteoarthritis; urocortin.

MeSH terms

  • Cartilage, Articular* / metabolism
  • Cell Death
  • Chondrocytes / metabolism
  • Humans
  • Ion Channels / metabolism
  • Osteoarthritis* / etiology
  • Osteoarthritis* / metabolism
  • Urocortins / metabolism
  • Urocortins / pharmacology

Substances

  • Ion Channels
  • PIEZO1 protein, human
  • Urocortins

Grants and funding

R.C.J. and S.M.H. were supported via Biotechnology and Biological Sciences Research Council Doctoral Training Partnership PhD awards (BB/M011208/1). K.M.L. was supported via an Medical Research Council Confidence in Concept 2014—The University of Manchester award (MC_PC_14112 v.2) and a Biotechnology and Biological Sciences Research Council Impact Accelerator account award (BB/S506692/1 and BB/P024424/1). Funding was received from the National Institute for Health Research Manchester Biomedical Research Centre, which supported consumables and technical support (Sonal Patel).